PORTAL VEIN THROMBOSIS THERAPEUTIC AGENT

WIPO Patent Application WO/2018/221480

A1

[Problem]To provide a novel technique, which is more effective in the treatment of portal vein thrombosis. [Solution] This portal vein thrombosis therapeutic agent contains an antithrombin III as an active ingredient, is administered to patients with portal vein thrombosis in an antithrombin III-administered dosage of 1000-3600 IU/day for 5 days, and is re-administered at an interval of 0-4 days in the same dosage and period.

WO/2021/223422	ANTI-HIV POLYPEPTIDE MODIFIED WITH HIGH MOLECULAR PEG, PREPARATION THEREFOR, AND USE THEREOF
WO/2007/006101	SURFACE PROTEINS OF PASTEURELLA MULTOCIDA
WO/2015/163533	COMPOSITION FOR PREVENTING OR TREATING SEPSIS OR SEPTIC SHOCK, COMPRISING ADK PROTEIN AS ACTIVE INGREDIENT

TANAKA CHIE (JP)
INOUE TAKAYUKI (JP)

PCT/JP2018/020441

December 06, 2018

May 29, 2018

Click for automatic bibliography generation  

NIHON PHARMACEUTICAL CO LTD (JP)

A61K38/16; A61P7/02

TAKATORI, H. ET AL.: "Danaparoid sodium monotherapy for portal vein thrombosis in cirrhotic patients is as effective as combination therapy with antithrombin III", HEPATOLOGY, vol. 58, no. 4, 2013, pages 894A
OKUWAKI, YUSUKE ET AL.: "Effectiveness of AT -3 Pharmaceutical Dosage for Portal Thrombosis", JAPANESE JOURNAL OF PORTAL HYPERTENSION, vol. 11, no. 1, pages 72
MURAKAMI, SATOSHI ET AL.: "Discussion of Effectiveness of AT -III Dosage for Portal Thrombosis", THROMBOSIS, vol. 41, pages A131
TADA, KAZUHIRO ET AL.: "A Case of Liver Cirrhosis with Portal Thrombosis in which Antithrombin III was Highly Effective", KANZO, vol. 42, no. 3, 2001, pages A544

MIZUNO, Katsufumi et al. (JP)

View/Download PDF      PDF Help

Previous Patent: NOVEL FLUORESCENT SUBSTANCE FOR TRANSPORTER FUNCTION ANALYSIS

Next Patent: LIQUID CRYSTAL DISPLAY DEVICE